6505--Hydralazine HCL Injections Award - Hikma Pharmaceuticals
Awarded Limited / Sole Source Justification Posted
- Solicitation number
- 36E79725R0048
- Agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 36E79726D0001-36E79726D0001 Federal IDV award
- Awardee
- Hikma Pharmaceuticals USA Inc.
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Points of contact
-
- Nicholas McGregor nicholas.mcgregor@va.gov (708) 786-4934
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Veterans Affairs National Acquisition Center issued this Limited/Sole Source Justification Notice for the procurement of Hydralazine Hydrochloride (HCL) 20mg/ML 1ML injections, a pharmaceutical preparation classified under NAICS 325412. The procurement was restricted to U.S.-made products under FAR 6.302-7 (public interest) as part of a pilot program aligned with Executive Order 14005 to strengthen domestic pharmaceutical manufacturing and reduce supply chain disruptions. Hikma Pharmaceuticals USA Inc., located in Berkeley Heights, New Jersey, was awarded contract 36E79726D0001 for $2,371,481.00 on November 21, 2025, based on being the lowest price technically acceptable and responsible offeror offering a U.S.-made product. The contract encompasses an estimated annual usage of 82,630 vials with a base year and four pre-priced option years structured as a single-award, firm-fixed price, indefinite delivery requirements contract. Although the procurement did not provide for full and open competition, the solicitation was posted to SAM.gov to ensure transparency and consideration of all eligible U.S.-made product offerors, with approval for the limited competition determination provided by the Secretary of Veterans Affairs on June 25, 2025.
Notice text
This acquisition did not provide for full and open competition in accordance with FAR 6.302-7. While this acquisition did not provide for full and open competition, the solicitation was posted to SAM.gov and all offerors of U.S.-made product were considered. See the attached justification document for details. Awarded contract 36E79726D0001 to HIKMA PHARMACEUTICALS USA INC. for 2371481.00000000 on 2025-11-21.
Files
| File | Type | Posted |
|---|---|---|
| 36E79726D0001_2.docx | DOCX document | |
| Justification for Other than FO Competition - Hydralazine.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Limited / Sole Source Justification | |
| 6505--Hydralazine HCL Injections Award - Hikma Pharmaceuticals | Award Notice | |
| 6505--Hydralazine Injection | Solicitation | |
| 6505--Hydralazine Injection | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| 6505--Ramipril Capsules RFP | National Acquisition Center | No set-aside | |
| 6505--VA Long Beach Pylarify | Veterans Integrated Service Network 22 | No set-aside | |
| 6505--FY27 Lenalidomide BPA | Veterans Integrated Service Network 22 | No set-aside | |
| 6505--Sacubitril/Valsartan Tablets (VA-27-00014055) | National Acquisition Center | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity